Objective-The activity of eicosanoid pathways is critical to the inflammatory and immune responses that are associated with the progression of atherosclerosis. Yet, the signals that regulate these pathways are poorly understood. Here, we address whether the innate immune signals of nucleotide-binding oligomerization domain-containing protein (NOD) 2 affect eicosanoids metabolism in atherosclerosis. Approach and Results-Analysis of human carotid plaques revealed that NOD2 was abundantly expressed at both mRNA and protein levels by endothelial cells and macrophages. Stimulation of NOD2 in ex vivo-cultured carotid plaques by muramyl dipeptide, an extrinsic ligand of NOD2, led to release of prostaglandin E 2 , upregulation of cyclooxygenase-2 and microsomal prostaglandin E synthase-1, and to downregulation of cyclooxygenase-1. NOD2 was coexpressed with cyclooxygenase-2 in lesional macrophages. NOD2-induced cyclooxygenase-2 expression in macrophages was dependent on p38 mitogen-activated protein kinase activation and was mediated by interleukin-1β and tumor necrosis factor-α. Selective lipidomic analysis of the eicosanoids released by the carotid plaques characterized the metabolites of 12-, 5-, and 15-lipoxygenase as the predominant eicosanoids that were produced by the atherosclerotic lesion in the absence of additional stimuli. Unlike the prostaglandin E 2 pathway, metabolic activity of the lipoxygenase pathways was not altered on the short-term activation of NOD2 in carotid plaques. Conclusions-These results suggest that atherosclerosis may involve enhanced NOD2-mediated innate immunity.
I
nnate immune activation by pathogen pattern recognition receptors has been implicated in the pathogenesis of atherosclerosis, 1 on the basis of evidence that toll-like receptors (TLRs), such as TLR4 and TLR2, are linked to active inflammatory signaling pathways in human atherosclerotic lesions. 2, 3 In addition to TLRs, cytoplasmic nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) have recently been reported as central regulators of immune and inflammatory responses in human inflammatory diseases, including atherosclerosis. 4 NLR comprise a diverse group of ≈25 receptors. NOD2, the NLR member to be initially characterized, contains 2 caspase recruitment domains (CARD) in its N-terminal region for signaling, a nucleotide-binding and oligomerization domain in its central region, and leucine-rich repeats in its C terminus for sensing muramyl dipeptide (MDP), a component of most types of peptidoglycan in Gram-positive and Gram-negative bacteria. 5, 6 On stimulation with MDP, NOD2 oligomerizes through its central NOD domain and recruits the serine/threonine kinase receptor-interacting protein 2 (also called RICK2) through CARD-CARD interactions, ultimately activating nuclear factor κB and mitogen-activated protein kinase (MAPK) pathways. 7 NOD2 has also been implicated in the activation of interferon response factor 3-dependent interferon-β production on viral RNA recognition through a receptor-interacting protein 2-independent mechanism. 8 The involvement of NOD2 in inflammatory diseases was initially suggested by the observation that mutations in CARD15, encoding NOD2, were linked to the susceptibility to Crohn disease. 9 ,10 CARD15 variants are also associated with an increased risk of developing angiographically documented coronary atherosclerosis and clinical destabilization of coronary plaques. 11 A recent study on NOD2-deficient mice demonstrated that NOD2 inhibits the migration and proliferation of vascular smooth muscle cells on tissue injury. 12 Notably, bacterial peptidoglycan, the natural ligand of NOD1 and NOD2, is present in atheromatous lesions, particularly those that showed marked inflammation and a vulnerable plaque phenotype. 13 However, little is known about the involvement of NOD2 in human atherosclerosis and its relevance to vascular inflammation.
Eicosanoids are potent bioactive lipid molecules, the synthesis of which is initiated by the release of arachidonic acid (AA) from membrane glycerophospholipids through cytosolic phospholipase A 2 α. Subsequently, the AA is converted into prostaglandins, leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids (HETEs)-collectively termed eicosanoids-by cyclooxygenases, lipoxygenases, and terminal enzymes.
Eicosanoids have a complex profile of activities with regard to pro-and antiatherogenic processes.
14 Eicosanoids affect the immune system by modulating cytokine signaling, cell differentiation, survival, migration, antigen presentation, and cell death. By acting on various aspects of immunity and inflammation, eicosanoids mediate acute inflammation and govern chronic inflammation in atherosclerosis. 15, 16 Prostaglandin E 2 (PGE 2 ), an inflammatory lipid mediator in the eicosanoid family, has been studied extensively. 15 PGE 2 production depends on the activity of 2 cyclooxygenasescyclooxygenase-1 and cyclooxygenase-2-and prostaglandin E synthases (PGESs), such as cytosolic PGES and type 1 and type 2 membrane-bound PGES (mPGES-1 and mPGES-2). 15, 17 Cyclooxygenase-1 and cytosolic PGES are constitutively expressed in most cell types, including vascular endothelial cells and smooth muscle cells. In contrast, basal expression of cyclooxygenase-2 and mPGES-1 is low, but both are rapidly induced at the site of inflammation.
In vivo activation of NLRs, such as NLR family, apoptosis inhibitory protein 5/NLR family, CARD-domain-containing 4 inflammasome has been shown to induce strong generation of prostaglandins and leukotrienes, 18 suggesting that NLRs are the crucial regulator of eicosanoids. Here, we examined the regulation of eicosanoid pathways by a previously unrecognized NLR member, NOD2, in ex vivo-cultured human carotid plaques.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

NOD2 Is Abundant in Atherosclerosis
To characterize the involvement of NOD2 in atherosclerosis, we first measured NOD2 transcript levels in 38 human carotid plaques. NOD2 transcript levels were upregulated 4-fold in atherosclerotic plaques versus healthy mammary arteries ( Figure 1A) , consistent with the significant increase in NOD2 protein in atherosclerosis, as validated in an analysis of 120 carotid plaque samples from a prospective cohort, AtheroExpress ( Figure 1B) . By immunostaining analysis, NOD2 localized preferentially to inflamed areas in the atherosclerotic lesion and was expressed by endothelial cells that lined the lumen of the diseased vessel. NOD2 was virtually undetectable in healthy arteries ( Figure 1C ). Double immunofluorescent staining for NOD2 and CD163, CD68, or von Willebrand Factor demonstrated that lesional NOD2 was expressed predominantly by macrophages and endothelial cells ( Figure 1D ). These expression data suggest that atherosclerosis is associated with increased NOD2-mediated innate immunity, secondary to its upregulation in endothelial cells and macrophage infiltration.
Transcriptional Upregulation of NOD2 in Atherosclerosis
Recent studies suggest that NOD2 transcription is regulated by proinflammatory cytokines and TLR signaling. 19, 20 To determine whether the increase in NOD2 expression in atherosclerosis results from transcriptional upregulation in response to immune stimuli, NOD2 and NOD1 expressions were measured in atherosclerotic plaques after treatment with lipopolysaccharide and MDP, selective agonistic ligands of TLR4 and NOD2, respectively. NOD2 was upregulated on lipopolysaccharide or MDP stimulation, whereas expression of NOD1 was unaltered ( Figure I in the online-only Data Supplement). These results suggest that the increased expression of NOD2 in atherosclerotic lesions can be attributed in part to in situ transcriptional upregulation in the inflammatory milieu.
Analysis of NOD2 Responsive Eicosanoids in Human Atherosclerosis
Atherosclerotic tissues synthesize various eicosanoids, each of which can function as an innate immune signal with specific effects. To determine the eicosanoid pathways that react specifically to NOD2 activation in atherosclerosis, we performed liquid chromatography coupled with tandem mass spectrometry to simultaneously analyze representative products of the major cyclooxygenase and lipoxygenase pathways in human atherosclerotic tissue. We observed distinct eicosanoid profiles between basal conditions and NOD2 activation. Under basal conditions, carotid plaques synthesized predominantly 6-keto-PGF 1α (a metabolite of PGI 2 )-along with relatively little PGE 2 , PGF 2α , and the thromboxane A 2 metabolite thromboxane B 2 . These data indicate that the intrinsic biosynthesis of PGI 2 was preserved in atherosclerotic tissue ( Figure 2A) . Notably, activation of NOD2 in carotid plaques affected a ≈10-fold increase in supernatant PGE 2 levels from baseline, whereas the levels of PGF 2α , 6-keto-PGF 1α , and thromboxane B 2 rose to a lesser extent compared with their baselines (Figure 2C-2F) . A similar pattern of prostaglandin responses was observed in 3 other atherosclerotic tissue cultures. These results establish that NOD2 activation in atherosclerotic tissue preferentially upregulates PGE 2 .
We also examined lipoxygenase pathway activity by analyzing the 5-lipoxygenase metabolite 5-HETE, 12-lipoxygenase metabolite 12-HETE, and 15-lipoxygenase-1 metabolite 13-hydroxyoctadecadienoic acid. 12-HETE was the most abundant eicosanoid, at levels ≈40-fold greater than the PGI 2 metabolite 6-keto-PGF 1α , in carotid plaques without NOD2 stimulation (Figure 2A ). 5-HETE and 13-hydroxyoctadecadienoic acid levels were 6-and 7-fold higher than those of 6-keto-PGF 1α , respectively. Notably, the levels of these lipoxygenase products were unaltered from baseline after NOD2 activation. These results suggest that lipoxygenase pathways, and in particular the 12-lipoxygenase pathway, dominate eicosanoid biosynthesis and metabolism in the basal condition.
Regulation of PGE 2 Pathway by the Activation of NOD2 in Atherosclerosis
To determine the mechanism of NOD2-induced PGE 2 , we measured the expression of cyclooxygenase-2, mPGES-1, and cyclooxygenase-1 in atherosclerotic plaques after activation of TLR4 with lipopolysaccharide, NOD1 with lauroyl-γ-Dglutamyl-meso-diaminopimelic acid (C12DAP), and NOD2 with MDP. Similar to the effects of TLR4, NOD2 activation enhanced PGE 2 production, which was accompanied by upregulation of cyclooxygenase-2, mPGES-1 and PGE 2 receptor, EP 2 and EP 4 in plaques ( Figure 3A-3F ). In contrast, cyclooxygenase-1 mRNA levels fell after lipopolysaccharide, C12DAP, and MDP treatment ( Figure 3B ). In addition, stimulation of plaque NOD2 also induced cytokine expression and release ( Figure 3G-3L) , indicative of an important role for NOD2 in the regulation of atherosclerosis-associated inflammation.
By immunostaining analysis, we detected that cyclooxygenase-2 colocalized with NOD2 in lesional macrophages ( Figure IIA -IIC in the online-only Data Supplement). Moreover, on analysis of the data in BiKE, a human carotid plaque biobank, we also noted a positive correlation between NOD2 and cyclooxygenase-2 and mPGES-1 ( Figure IID and IIE in the online-only Data Supplement). Together, these data suggest that NOD2 and the PGE 2 pathway may interact in macrophages in atherosclerosis.
PGE 2 Is the Downstream Signaling Mediator of NOD2 Activation in Human Macrophages
To examine the relationship between NOD2 and the PGE 2 pathway in macrophages, we treated human monocyte-derived macrophages with MDP. MDP upregulated cyclooxygenase-2 and mPGES-1 ( Figure 4A and 4B) and affected a rapid increase in PGE 2 production ( Figure 4C) . By Western blot, we confirmed that MDP induced cyclooxygenase-2 and mPGES-1 dose dependently and downregulated cyclooxygenase-1 ( Figure 4D ). Stimulation of macrophage TLR4 or NOD2 also upregulated EP4 and EP2 ( Figure 4E-4G) . These results indicate that NOD2 elicits PGE 2 by inducing the expression of enzymes that mediate its biosynthesis, and further escalates the effect of PGE 2 by upregulating its receptors.
Activation of p38 MAPK and Interleukin-1β Mediate NOD2-Induced PGE 2 Production
To determine the signaling mechanisms of NOD2-driven upregulation of the PGE 2 pathway, we examined the responses of MAPK and nuclear factor-κB in macrophages to NOD2 stimulation. Stimulation of macrophages by MDP was shown to provoke robust and prolonged phosphorylation of p38 and activation of nuclear factor-κB, as evidenced by the increase in phosphorylated p65 and the decline in IκBα ( Figure 5A ). Furthermore, MDP also weakly activated extracellular signalregulated kinase 1/2 and c-Jun N-terminal kinase ( Figure 5A ). However, pharmacological inhibition of individual MAPKs suggested that p38 activation was indispensible for NOD2-mediated induction of PGE 2 pathways ( Figure 5B ).
Previous studies have suggested that interleukin-1β and tumor necrosis factor (TNF)-α are the potent inducer of PGE 2 . 21, 22 To verify their function in NOD2-induced PGE 2 , we blocked interleukin-1β and TNF-α with an interleukin-1β receptor antagonist (interleukin-1RA) and TNF-α-neutralizing antibody (anti-TNF-α), respectively. Consistent with previous findings, our data show that interleukin-1β and TNF-α are critically involved in the induction of cyclooxygenase-2 and PGE 2 by NOD2 ( Figure 5C and 5D).
Regulation of the 5-Lipoxygenase Pathway in Atherosclerosis
Leukotrienes are another important group of eicosanoid mediators that link innate and adaptive immunity in atherosclerosis. [23] [24] [25] Leukotrienes are synthesized by macrophages from AA through the 5-lipoxygenase pathway in atherosclerosis. 26 We sought to determine the function of NOD2 in the regulation of the 5-lipoxygenase pathway, examining the expression of enzymes that participate in the biosynthesis of leukotrienes-5-lipoxygenase-and 5-lipoxygenase-activating protein-in human macrophages after lipopolysaccharide and MDP stimulation. NOD2 and TLR4 failed to alter the transcription of 5-lipoxygenase-or 5-lipoxygenase-activating protein in human macrophages ( Figure IIIA and IIIB in the online-only Data Supplement). Consistent with the effects of 5-HETE (Figure 2) , the constitutive production of leukotriene B 4 and leukotriene E 4 was unaffected by NOD2 stimulation ( Figure IIIC and IIID in the online-only Data Supplement). We conclude that acute activation of NOD2 is dispensable to the regulation of the 5-lipoxygenase pathway and leukotriene biosynthesis in atherosclerosis.
Discussion
Although significant progress has recently been made in understanding of NOD2-mediated innate immune mechanism in the pathogenesis of inflammatory diseases, this study provides additional insights on NOD2 in atherosclerosis. Our findings show that human atherosclerosis is characterized by high NOD2 expression in endothelial cells and macrophages. Because NOD2 is readily induced in macrophages and endothelial cells by proinflammatory cytokines 20 and innate immune signaling, 5 the rise in NOD2 in atherosclerotic lesions is attributable to transcriptional upregulation in the local inflammatory milieu and massive infiltration of macrophages. Compared with the little NOD2 in health arteries, its abundance in lesions signifies that the activity of human atherosclerosis is associated with enhanced NOD2-mediated innate immunity.
To obtain direct proof of the function of NOD2 in human atherosclerosis, we developed an ex vivo tissue culture system that mimics aspects of the inflammatory milieu in atherosclerotic lesions. Using this model, we examined the function of NOD2 in regulating eicosanoid pathways on innate immune activation in atherosclerosis. We observed many notable features of spontaneous eicosanoid biosynthesis in the atherosclerotic plaque. The production of PGI 2, as reflected by its metabolite 6-keto PGF 1α in the supernatant, remained high relative to other prostanoids, suggesting that PGI 2 pathway activity remained robust in atherosclerotic lesions. Compared with PGI 2 , the levels of PGE 2 , PGF 2α , and thromboxane B 2 were minute at baseline reflecting that mPGES-1, PGF synthase, and thromboxane synthase are virtually inactive. The functional relevance of this prostanoid profile is unknown, but it might explain in part why use of nonsteroidal anti-inflammatory drugs increases the risk of myocardial infarction and stroke. 27, 28 Our data also suggest that metabolites of lipoxygenase pathways, including 5-lipoxygenase, 15-lipoxygenase-1, and 12-lipoxygenase, represent the dominant eicosanoids in atherosclerosis. In particular, the levels of 12-HETE were the highest of the eicosanoids that we analyzed (Figure 2 ). In humans, 12-HETE is formed by oxidation of AA by 12-lipoxygenase. On the basis of potential association between 12-lipoxygenase in atherosclerosis and atherothrombotic events 29 and on its function in eliciting inflammation, 30, 31 targeting the respective 12-lipoxygenase pathway is a potential therapeutic approach for atherosclerosis.
Because of limited quantities of the samples, our study was unable to assess activities of the 15-lipoxygenase pathway in human atherosclerosis. By comparative analysis of the 12-and 15-lipoxygenase pathways, a recent study reported that the expression and the activity of 15-lipoxygenase-2 are higher than other 12-and 15-lipoxygenase in human atherosclerosis. 29 These observations suggest that in addition to 12-lipoxygenase, 15-lipoxygenase-2 is another prevalent eicosanoid pathway in atherosclerosis. However, further study is required to define the function of innate immunity in regulation of the 15-lipoxygenase-2 pathway in atherosclerosis.
Macrophages are the primary source of eicosanoids, which are fundamental to the inflammation and immune activity in atherosclerosis. Previous studies showed that activation of macrophage TLR4 leads to the increased production of PGE 2 through upregulation of cyclooxygenase-2 , indicative of PGE 2 as a central signaling component that contributes to TLR4-mediated innate immunity. However, the potential pattern recognition receptor that governs PGE 2 synthesis in human atherosclerosis has not been defined. We demonstrated that NOD2 may represent another important innate immune recognition that regulates the PGE 2 pathway in atherosclerosis. Short-term stimulation of NOD2 in macrophages evokes the production of PGE 2 through upregulation of cyclooxygenase-2 and the PGE 2 -specific synthase mPGES-1. In addition, we showed that NOD2 is also linked to the production of cytokines that are critical to vascular inflammation. These findings establish the involvement of NOD2-mediated innate immunity in atherosclerosis.
We found that activated p38 is a central transcriptional signaling mechanism that relays NOD2-induced innate eicosanoid signaling. p38 is the most pathophysiologically significant MAPK with regard to the inflammatory responses that are associated with atherosclerosis. Activated p38 orchestrates the expression of many proinflammatory mediators, including cytokines, chemokines, and adhesion molecules, that promote atherosclerosis. [32] [33] [34] p38 also governs the expression of macrophage scavenger receptors, thus controlling the uptake of oxidized low-density lipoprotein. 33 Finally, p38 is a central signal that directs cell growth and migration. 35 Thus, we postulate that through activation of p38, NOD2 participates in various pathogenic processes of atherosclerosis. Consistent with previous observations, 37 NOD2 also signals to nuclear factor-κB, interleukin-1β, and TNF-α in human macrophages. Notably, NOD2-induced interleukin-1β and TNF-α are indispensable in the upregulation of the cyclooxygenase 2-PGE 2 axis, possibly through autocrine regulation of MAPK. These observations increase our understanding of the NOD2-mediated signaling network in atherosclerosis.
The signal-activated generation of bioactive eicosanoids is initiated by liberating AAs from phospholipids by activation of phospholipase A 2 (PLA 2 ). Whether PLA 2 regulates NOD2-triggered PGE2 production remains to be defined. Recent studies have shown that stimulation of TLR2, TLR3, or TLR4 leads to MAPK-dependent, coordinated activation of cytosolic PLA 2 and secretory PLA 2. 38,39 On the basis of resemblance of NOD2 to TLR4 in downstream signaling pathways, it is plausible that activation of PLA 2 by NOD2 signaling is an important mechanism in the regulation of eicosanoid pathways.
The implications of NOD2-mediated PGE2 signaling in atherosclerosis are likely to be intricate because PGE 2 has proinflammatory and anti-inflammatory effects depending on the context of cell type and PGE 2 receptor subtype. NOD2-induced PGE 2 production is concurrent with the enhanced expression of EP 2 and EP 4 in human atherosclerotic plaques, and EP 4 is preferentially upregulated in macrophages by NOD2, potentially favoring EP 4 -related activities. These findings increase our understanding of how NOD2 shapes innate immune responses in atherosclerosis.
Leukotrienes are another group of eicosanoid mediators with significant functions in atherosclerosis. 23, 40, 41 Leukotrienes are produced in various leukocytes-preferentially in macrophages and mast cells-through the concerted activity of 5-lipoxygenase and 5-lipoxygenase-activating protein in diseased vessels. 42 In addition to transforming growth factor β and 1,25(H)D3, 43 lipopolysaccharide, 44 and the TLR7/8 agonist Resiquimod (R-848) 45 upregulate leukotriene B4, suggesting that increased leukotriene levels result from innate immune activation. However, the significance of NOD2 in the regulation of 5-lipoxygenase pathway and biosynthesis of leukotrienes is unknown.
In summary, these results imply that atherosclerosis is accompanied by enhanced NOD2-mediated innate immune activity. NOD2 is implicated for the induction of PGE 2 through upregulation of cyclooxygenase-2 and mPGES-1 in lesional macrophages on activation. However, lipoxygenase pathways dominate the basal process of eicosanoid synthesis and metabolism in atherosclerosis without additional innate immune activation. This study affords new perspectives on the functional relevance of NOD2 to heightened inflammation in atherosclerosis.
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